Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-β

Journal of Immunotherapy

Volumn 30, Issue 3, 2007, Pages 261-273

  Gomez, German G ^a   Kruse, Carol A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Apoptosis; Astrocytomas; CTL; IL 6; IL 8

Indexed keywords

CARMUSTINE; FAS LIGAND; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ALLOGENEIC RESTRICTION; ALLOIMMUNITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL POPULATION; CONTROLLED STUDY; CROSS RESISTANCE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; GAMMA RADIATION; GLIOMA; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOLECULAR CLONING; PHENOTYPE; PRIORITY JOURNAL; TUMOR IMMUNITY; UPREGULATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CALCIUM; CARMUSTINE; CELL ADHESION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; EXTRACELLULAR MATRIX; FAS LIGAND PROTEIN; GAMMA RAYS; GLIOMA; HLA-A ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, LYMPHOKINE-ACTIVATED; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 34247115020     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211339.81211.25     Document Type: Article

References (80)

1. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States; 2005.
2. Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin. 1998;48:331-360, 321.
3. Medewar P. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
4. Dix AR, Brooks WH, Roszman TL et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100:216-232.
5. Kruse CA, Mitchell DH, Lillehei KO, et al. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. Cancer. 1989;64:1629-1637.
6. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A. 1996;93:909-2914.
7. Baxevanis CN, Reclos GJ, Gritzapis AD, et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer. 1993;72:491-501.
8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
9. Virasch N, Kruse CA. Strategies using the immune system for therapy of brain tumors. Hematol Oncol Clin N Am. 2001;15:1053-1071.
10. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100-108.
11. Rosenberg SA, Yang JC, Robbins PF, et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003;26:385-393.
12. Gately CL, Muul LM, Greenwood MA, et al. In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J Immunol. 1984;133:3387-3395.
13. Fiore E, Fusco C, Romero P, et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene. 2002;21:5213-5223.
14. Ruiz-Cabello F, Cabrera T, Lopez-Nevot MA, et al. Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Sem Cancer Biol. 2002;12:15-24.
15. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997;158:4521-4524.
16. Kruse CA, Beck LT. Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotechnol Appl Biochem. 1997;25:197-205.
17. Kruse CA, Cepeda L, Owens B, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother. 1997;45:77-87.
18. Kruse CA, Rubinstein D. Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors. In: Liau LM, Becker DP, Cloughesy TF, et al, eds. Brain Tumor Immunotherapy. Totowa, NJ: Humana Press; 2001:149-170.
19. Gomez GG, Varella-Garcia M, Kruse CA. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. Cancer Genet Cytogenet. 2006;165:121-134.
20. Gomez GG, Kruse CA. Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulated Apaf-1 is implicated with immune resistance. Submitted 2006.
21. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, et al. Characterization of a continuous human glioma cell line DBTRG-05 MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In vitro Cell Dev Biol. 1992;28A:609-614.
22. Kruse CA, Visonneau S, Kleinschmidt-DeMasters BK, et al. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res. 2000;60:5731-5739.
23. O'Connor R, Cesano A, Lange B, et al. Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood. 1991;77:1534-1545.
24. Modiano JF, Sun J, Lang J, et al. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clin Immunol. 2004;112:54-65.
25. Read SB, Kulprathipanja NV, Gomez GG, et al. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Int Cyt Res. 2003;23:379-393.
26. Gomez GG, Read SB, Gerschenson LE, et al. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro-Oncol. 2004;6:83-95.
27. Frost P, Caliliw R, Belldegrun A, et al. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol. 2003;22:431-437.
28. Ohnishi T, Taki T, Hiraga S, et al. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun. 1998;245:319-324.
29. Giese A, Loo MA, Tran N, et al. Dichotomy of astrocytoma migration and proliferation. Int J Cancer. 1996;67:275-282.
30. Mattern RH, Read SB, Pierschbacher MD, et al. Glioma cell integrin expression and their interactions with integrin antagonists: research article. Cancer Ther. 2005;3A:325-340.
31. Simon MM, Waring P, Lobigs M, et al. Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. J Immunol. 2000;165:3663-3672.
32. Kamarajan P, Sun NK, Chao CC. Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. Biochem J. 2003;376:253-260.
33. Norman SA, Rhodes SN, Treasurywala S, et al. Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display. Cancer. 2000;89:850-862.
34. Gately MK, Glaser M, McCarron RM, et al. Mechanisms by which human gliomas may escape cellular immune attack. Acta Neurochir (Wien). 1982;64:175-197.
35. Oberc-Greenwood MA, Muul LM, Gately MK, et al. Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro. J Neuro-oncol. 1986;3:387-396.
36. Schiltz PM, Gomez GG, Read SB, et al. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes. J Int Cyt Res. 2002;22:1209-1216.
37. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol. 1999;43:203-211.
38. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;168:4772-4780.
39. Lin JT, Martin SL, Xia L, et al. TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet. J Immunol. 2005;174:5950-5958.
40. Medema JP, de Jong J, van Hall T, et al. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med. 1999;190:1033-1038.
41. Hiraki A, Ono T, Tanaka M, et al. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis. Anticancer Res. 2001;21:2561-2567.
42. Dick SJ, Macchi B, Papazoglou S, et al. Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism. Science. 1983;220:739-742.
43. Hemesath TJ, Marton LS, Stefansson K. Inhibition of T cell activation by the extracellular matrix protein tenascin. J Immunol. 1994;152:5199-5207.
44. Slingluff CL Jr, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48:661-672.
45. Rivoltini L, Gambacorti-Passerini C, Supino R, et al. Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance. Int J Cancer. 1989;43:880-885.
46. Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J Immunol. 1990;144:4487-4495.
47. Chang CC, Campoli M, Restifo NP, et al. Immune selection of hotspot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol. 2005;174:1462-1471.
48. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol. 1994;153:1225-1237.
49. Hiraki A, Ikeda K, Yoshino T, et al. Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele. Biochem Biophys Res Commun. 2001;286:786-791.
50. Onno M, Guillaudeux T, Amiot L, et al. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol. 1994;41:79-86.
51. Riteau B, Faure F, Menier C, et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol. 2003;64:1064-1072.
52. Mullbacher A, Lobigs M, Hla RT, et al. Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. J Immunol. 2002;169:145-150.
53. Bass HZ, Yamashita N, Clement LT. Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. II. Differential effects of IL-6 on the helper cell-independent generation of CTL from CD8+ precursor subpopulations. J Immunol. 1993;151:2895-2903.
54. Van Meir E, Ceska M, Effenberger F, et al. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res. 1992;52:4297-4305.
55. Van Meir E, Sawamura Y, Diserens AC, et al. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 1990;50:6683-6688.
56. Lichtor T, Libermann TA. Coexpression of interleukin-1 beta and interleukin-6 in human brain tumors. Neurosurg. 1994;34:669-672.
57. Choi C, Gillespie GY, Van Wagoner NJ, et al. Fas engagement increases expression of interleukin-6 in human glioma cells. J Neuro-oncol. 2002;56:13-19.
58. Choi C, Xu X, Oh JW, et al. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res. 2001;61:3084-3091.
59. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncol. 2005;7:122-133.
60. Ward SG, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem J. 1998;333(Pt 3):457-470.
61. Graf MR, Prins RM, Merchant RE. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol. 2001;166:121-129.
62. Gomez GG, Kruse CA. Subsets within alloreactive CTL exhibit upregulated proinflammatory cytokine secretion: aCTL response to coincubation with irrelevant and relevant parental and immunoresistant gliomas. 2006 Experimental Biology meeting abstracts [on CD-ROM]. FASEB J. 2006;20:Abstract 697.4.
63. Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2005;55:1-11.
64. Book AA, Fielding KE, Kundu N, et al. IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2. J Neuroimmunol. 1998;92:50-59.
65. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 2000;165:4773-4777.
66. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989;143:3222-3229.
67. Constam DB, Philipp J, Malipiero UV, et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148:1404-1410.
68. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer. 2000;89:251-258.
69. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
70. Geissmann F, Revy P, Regnault A, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol. 1999;162:4567-4575.
71. Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991-998.
72. Smyth MJ, Strobl SL, Young HA, et al. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol. 1991;146:3289-3297.
73. Lin CM, Wang FH, Lee PK. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer. Clin Immunol. 2002;102:96-105.
74. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369-380.
75. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64:7596-7603.
76. Jachimczak P, Bogdahn U, Schneider J, et al. The effect of transforming growth factor-beta 2-specific phosphorothioate-antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg. 1993;78:944-951.
77. Witham TF, Villa L, Yang T, et al. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol. 2003;64:63-69.
78. Weinshenker BG, Hebrink D, Kantarci OH, et al. Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis. J Neuroimmunol. 2001;120:138-145.
79. Nishimura DY, Purchio AF, Murray JC. Linkage localization of TGFB2 and the human homeobox gene HLX1 to chromosome 1q. Genomics. 1993;15:357-364.
80. Munz C, Naumann U, Grimmel C, et al. TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. Eur J Immunol. 1999;29:1032-1040.